Mainz, November 27, 2018 – TRON is delighted to announce an article published in Chemical Society Reviews co-authored by Mustafa Diken. In collaboration with a European team of scientists working on nanomaterials in medicine, Dr. Diken provides an overview of the current state-of-the-art concerning nano- and macroscale materials and their application in immunotherapy. Covering current
TRON published an advertorial in the November 2018 issue of the Life Sciences magazine published by goingpublic.de. The advert featured TRON’s core competences and highlighted our leading edge research accomplishments. A PDF version of this article is available for download (German only).
Verona, September 27, 2018 – The Macrophage and Dendritic Cell Society is holding its 32nd annual meeting 27-29 September in beautiful Verona, Italy. This year’s theme is “the crossroad between macrophage and dendritic cells: from immunometabolism to single cell fate.” In this context, TRON’s Mustafa Diken is giving today’s Happy Hour Lecture, entitled “Bringing the
Mainz, September 2018 – TRON is proudly hosting a scholar from the Zoran Djindjic Program (ZDS). Created in 2003 after the assassination of the first democratically elected Prime Minister of Serbia, and supported by the German federal government, the aim of the program is to provide short internships in German institutions for highly qualified candidates
Mainz, September 2018 – TRON is sponsoring two scholarships in the Deutschlandstipendium 2018/2019 of the Johannes Gutenberg University Mainz, thereby supporting two young medical students as part of this Federal Ministry of Education and Research program. Scholarship holders were selected based on proven excellence, exceptional social commitment, and special social or family circumstances.
Mainz, September 6, 2018 – The University Cancer Center at the University Mainz is host to their 1st Science Day 2018 on September 6th 2018. The event features a variety of young investigators and established scientists presenting their research in the fields of cancer immunotherapy, genetic instability, epidemiology, or drug delivery. Our doctoral student Nadja
Mainz, August 22, 2018 – The Center for Thrombosis and Hemostasis (CTH) at the University Medical Center Mainz is host to a new Innovative Training Network (ITN) „TICARDIO – Thrombo-Inflammation in Cardiovascular Disease“. It will address the studies of pathological processes in cardiovascular diseases. The ITN offers 15 science graduate students the opportunity to develop
Mainz, August 10, 2018 – The new Helmholtz Institute “HI-TRON Mainz” aims to develop effective immunotherapies and identify new biomarkers for cancer treatments. HI-TRON is a collaboration between the German Cancer Research Center (DKFZ) and the research institute TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz. Cooperation agreements have
Mainz, August 10, 2018 – TRON is delighted to announce a Comment authored by Özlem Türeci and Ugur Sahin in the journal Nature Biomedical Engineering. “Challenges towards the realization of individualized cancer vaccines” discusses the challenges of optimizing vaccine design, manufacturing and affordability, and identifying the most suitable clinical setting(s). TRON colleagues Martin Löwer, Barbara
Mainz – TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz), a non-profit organization and internationally recognized leader in tumor immunology and cancer therapy research, has entered into a research collaboration with Astellas Pharma Inc., a company dedicated to improving the health of people through the provision of innovative and reliable
Trento, Italy, June 26, 2018 – Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small
Mainz, 17. Mai 2018 – Jeder Tumor ist anders. “Krebs entsteht durch individuelle Mutationen”, erklärt Prof. Dr. Ugur Sahin. “Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf